secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001683168-22-007279
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health hires CCO and COO for NeuroPharma; salaries contingent on $5M fundraising
--------------------------------------------------------------------------------

- Erik Emerson named CCO and Greg Gironda named COO of Odyssey NeuroPharma, effective Nov 1, 2022.
- Each receives one-year term at 33% part-time commitment; base salary of $125K payable only after company raises $5M.
- Each granted 600K stock options: 125K vest on signing, 300K upon $5M+ financing, 175K upon Nasdaq/NYSE listing.
- Executives bring over 50 years combined pharmaceutical commercialization experience.
- Odyssey aims to advance concussion and Niemann-Pick treatments through Phase II trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822007279/0001683168-22-007279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822007279/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-007279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer